FLT3, a transmembrane ligand-activated receptor tyrosine kinase, is expressed in hematopoietic progenitor cells, and 25–30% of AML cases carry FLT3 mutations that result in abnormal cell growth and survival via mTOR and PI3K/AKT pathway [34]. This evidence concerns the gene MTOR and acute myeloid leukemia.